Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.

SEC Filings

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

Filing date	Description	Form	Filing Group	View
May 14, 2020	Report of unscheduled material events or corporate event	8-K	Current Reports	0001564590-20-025252.pdf 0001564590-20-025252.rtf 0001564590-20-025252.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
May 14, 2020	Quarterly report which provides a continuing view of a company's financial position	10-Q	Quarterly Filings	0001564590-20-025260.pdf 0001564590-20-025260.rtf 0001564590-20-025260.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Jul 27, 2020	Report of unscheduled material events or corporate event	8-K	Current Reports	0001193125-20-199118.pdf 0001193125-20-199118.rtf 0001193125-20-199118.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Jul 27, 2020	Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3	424B5	Registration Statements	0001193125-20-199694.pdf 0001193125-20-199694.rtf 0001193125-20-199694.xls View HTML
Jul 29, 2020	Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3	424B5	Registration Statements	0001193125-20-202547.pdf 0001193125-20-202547.rtf 0001193125-20-202547.xls View HTML
Jul 31, 2020	Report of unscheduled material events or corporate event	8-K	Current Reports	0001193125-20-206368.pdf 0001193125-20-206368.rtf 0001193125-20-206368.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Aug 12, 2020	Report of unscheduled material events or corporate event	8-K	Current Reports	0001564590-20-039478.pdf 0001564590-20-039478.rtf 0001564590-20-039478.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Aug 12, 2020	Quarterly report which provides a continuing view of a company's financial position	10-Q	Quarterly Filings	0001564590-20-039480.pdf 0001564590-20-039480.rtf 0001564590-20-039480.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Aug 14, 2020	Official notification to shareholders of matters to be brought to a vote ("Proxy")	DEF 14A	Proxy Filings	0001193125-20-220330.pdf 0001193125-20-220330.rtf 0001193125-20-220330.xls View HTML
Aug 14, 2020	Additional proxy soliciting materials - definitive	DEFA14A	Proxy Filings	0001193125-20-220342.pdf 0001193125-20-220342.rtf 0001193125-20-220342.xls View HTML

Data provided by Kaleidoscope.

Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.